ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 6 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.British journal of cancer · 2022Pooled it
- A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.International journal of oncology · 2019Pooled it
- Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Guideline
- NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.Journal of the National Comprehensive Cancer Network : JNCCN · 2016Guideline
- Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry.Human genetics · 2012Pooled it
- Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Trial
- Genetic Polymorphisms and Antioxidant Reactions in Prostate Cancer.International journal of molecular sciences · 2026Review
- Genomic landscape and precision therapy in prostate cancer: current status and future directions.NPJ precision oncology · 2026Review
- Hereditary cancer syndromes with gynecological cancer risk: focus on prevention strategies.Frontiers in oncology · 2026Review
- Integrating molecular diagnostics for early prostate cancer detection.Oncoscience · 2025Article
- Germline BRCA2 Mutation and Lynch Syndrome in a Patient With Multiple Primary Malignancies.Case reports in oncological medicine · 2025Article
- Chest Pain as a Symptom of Early-Onset Metastatic Prostate Cancer: Exploring the Role of Screening.Cureus · 2025Article
- Frequency of Germline and SomaticCancers · 2023Review
- Prevalence of GermlineCancers · 2023Review
- Genetic medicine is accelerating in Japan.Breast cancer (Tokyo, Japan) · 2022Article
- Medicaid Expansions: Probing Medicaid's Filling of the Cancer Genetic Testing and Screening Space.Healthcare (Basel, Switzerland) · 2022Review
- Cancer Risks Associated WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview.The world journal of men's health · 2022Review
- Genetic predisposition to prostate cancer: an update.Familial cancer · 2022Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeProtein-truncating mutations in BRCA1 and in particular BRCA2 genes have been associated with prostate cancer. However, there is still uncertainty about the magnitude of association particularly with Gleason score, and family history of prostate, breast, and ovary cancers. EXPERIMENTAL
designTo further examine associations between three founder mutations located in BRCA1 (185delAG, 5382insC) or BRCA2 (6174delT) genes and prostate cancer, we conducted a study of 979 prostate cancer cases and 1,251 controls among Ashkenazi Jewish men. Detailed information was obtained on prostate cancer pathology, age at diagnosis, and family history of all cancers. Odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression models.
resultsProstate cancer risk was increased (OR, 1.9; 95% CI 0.9-4.1) for BRCA2 mutation carriers but not for BRCA1 mutation carriers. BRCA2 mutation carriers had an OR of 3.2 (95% CI, 1.4-7.3) for Gleason score of 7 to 10, but no association was observed for Gleason score of < 7. Carriers of BRCA1-185delAG mutation also had an OR of 3.5 (95% CI, 1.2-10.3) for Gleason score of > or =7 tumors; however, the association of either BRCA1-185delAG or 5382insC mutation was not statistically significant. Associations between founder mutations and prostate cancer were stronger in men with no first-degree family history of breast and/or ovarian cancers but were unaffected by family history of prostate cancer.
conclusionThese results indicate that the BRCA2 founder mutation confers a 3-fold elevated risk of high-grade prostate cancer. Although BRCA1 mutations were not associated with prostate cancer, the BRCA1-185delAG was associated with high Gleason score tumors. These findings should be carefully considered in genetic counseling and/or evaluating therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.